JAG1

Last updated
JAG1
Protein JAG1 PDB 2KB9.png
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases JAG1 , Jag1, ABE2, Gsfabe2, Htu, Ozz, Ser-1, AGS, AHD, AWS, CD339, HJ1, JAGL1, jagged 1, AGS1, DCHE, jagged canonical Notch ligand 1, CMT2HH
External IDs OMIM: 601920 MGI: 1095416 HomoloGene: 180 GeneCards: JAG1
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_000214

NM_013822

RefSeq (protein)

NP_000205

NP_038850

Location (UCSC) Chr 20: 10.64 – 10.67 Mb Chr 2: 136.92 – 136.96 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Jagged1 (JAG1) is one of five cell surface proteins (ligands) that interact with four receptors in the mammalian Notch signaling pathway. The Notch signaling pathway is a highly conserved pathway that functions to establish and regulate cell fate decisions in many organ systems. Once the JAG1-NOTCH (receptor-ligand) interactions take place, a cascade of proteolytic cleavages is triggered resulting in activation of the transcription for downstream target genes. Located on human chromosome 20, the JAG1 gene is expressed in multiple organ systems in the body and causes the autosomal dominant disorder Alagille syndrome (ALGS) resulting from loss of function mutations within the gene. JAG1 has also been designated as CD339 (cluster of differentiation 339).

Contents

Structure and function

JAG1 was first identified as a ligand that was able to activate notch receptors when the rat gene Jagged encoding a protein homolog was cloned in 1995. [5] [6] The structure of the JAG1 protein includes a small intracellular component, a transmembrane motif, proceeded by an extracellular region containing a cystine-rich region, 16 EGF-like repeats, a DSL domain, and finally a signal peptide totaling 1218 amino acids in length over 26 coding exons. [7]

The JAG1 protein encoded by JAG1 is the human homolog of the Drosophila jagged protein. [5] Human JAG1 is one of five ligands for receptors in the NOTCH signaling pathway which helps to determine cellular fate and is active during many developmental stages. The extracellular component of the JAG1 protein physically interacts with its respective Notch receptor. This interaction kicks off a cascade of proteolytic cleavages leading to the original NOTCH intracellular domain being trafficked into the nucleus of the cell leading to the activation of different target genes. [8] [9] [10] [11]

Expression profile and mouse studies

In situ hybridization and conditional gene knockout studies have helped to demonstrate the role JAG1 plays in development and its effects on different organ systems. In humans, JAG1 has broad expression in many tissue types including the pancreas, heart, placenta, prostate, lung, kidney, thymus, testis, and leucocytes in the adult. [12] In a developing embryo JAG1 expression is concentrated around the pulmonary artery, mesocardium, distal cardic outflow tract, major arteries, metanephros, branchial arches, pancreas, the portal vein, and otocyst. [12] Generally, JAG1 expression patterns correlate with organ systems affected in ALGS, although it is important to note that not all tissues where JAG1 is expressed are affected in ALGS. More recently JAG1 expression has been found to be altered in breast cancer and adrenocortical carcinoma patients. [13] [14]

Mouse models where the Jag1 gene is turned off in certain tissues (conditional knockout mouse models) have been used to study the role of Jag1 in many tissue specific areas. While homozygous deletions of Jag1 have been shown to be embryonic lethal in mice, and heterozygous deletions may show only a limited phenotype (involving the eye), mice haploinsufficient for both Jag1 and Notch2 present with the ALGS phenotype. [15] Conditional gene knockout mouse models with Jag1 mutations targeted to the portal vein mesenchyme, endothelium, and cranial neural crest all exhibit features classic to those in individuals with ALGS, highlighting the role of this tissue type in disease origins [16] [17] [18] [19] [20]

Disease phenotype

ALGS is an autosomal dominant multi-system disorder affecting several body systems including the liver, heart, skeleton, eye, facial structure, kidneys and vascular system. The most clinically significant concerns stem from liver, heart, vascular or renal problems. Mutations in JAG1 were first discovered to be responsible for ALGS by researchers at The Children's Hospital of Philadelphia and the National Institutes of Health in 1997. [6] Patients who are clinically consistent with the disorder usually have a mutation in JAG1 (94%), while a smaller 2% have a mutation in NOTCH2 . [21] Over half of individuals with mutations in the gene did not inherit it from either parent, and thus have a de novo mutation. [21] [22] JAG1 mutation types include protein truncating (splice site, frameshift, and nonsense), missense, and whole gene deletions accounting for 80%, 7%, and 12% respectively. Since all mutation types lead to a patient phenotype, it is thought that haploinsufficiency for JAG1 is the likely disease mechanism of action. [23] [24] [25] Although individuals can have a range of mutation types in JAG1, all of the known mutations lead to loss of the function of one copy, and, there is no correlation between mutation type or location and disease severity. Though individuals with ALGS have several body systems affected, there is a subset of individuals with JAG1 mutations who present with tetralogy of fallot/pulmonary stenosis that do not show the other clinical signs of the syndrome. [26] Given the variable expressivity of the disease, there may be other genetic or environmental modifiers present beyond the original JAG1 mutation.

More recently, JAG1 expression changes have been implicated in many types of cancer. Specifically, up regulation of JAG1 has been correlated with both poor overall breast cancer survival rates and an enhancement of tumor proliferation in adrenocortical carcinoma patients. [13] [27] [28] [29]

See also

Notes

Related Research Articles

<span class="mw-page-title-main">Notch signaling pathway</span> Series of molecular signals

The Notch signaling pathway is a highly conserved cell signaling system present in most animals. Mammals possess four different notch receptors, referred to as NOTCH1, NOTCH2, NOTCH3, and NOTCH4. The notch receptor is a single-pass transmembrane receptor protein. It is a hetero-oligomer composed of a large extracellular portion, which associates in a calcium-dependent, non-covalent interaction with a smaller piece of the notch protein composed of a short extracellular region, a single transmembrane-pass, and a small intracellular region.

<span class="mw-page-title-main">Alagille syndrome</span> Medical condition

Alagille syndrome (ALGS) is a genetic disorder that affects primarily the liver and the heart. Problems associated with the disorder generally become evident in infancy or early childhood. The disorder is inherited in an autosomal dominant pattern, and the estimated prevalence of Alagille syndrome is 1 in every 30,000 to 1 in every 40,000 live births. It is named after the French pediatrician Daniel Alagille, who first described the condition in 1969.

<span class="mw-page-title-main">Hajdu–Cheney syndrome</span> Medical condition

Hajdu–Cheney syndrome, also called acroosteolysis with osteoporosis and changes in skull and mandible, arthrodentoosteodysplasia and Cheney syndrome, is an extremely rare autosomal dominant congenital disorder of the connective tissue characterized by severe and excessive bone resorption leading to osteoporosis and a wide range of other possible symptoms. Mutations in the NOTCH2 gene, identified in 2011, cause HCS. HCS is so rare that only about 50 cases have been reported worldwide since the discovery of the syndrome in 1948

<span class="mw-page-title-main">Caveolin 3</span> Protein-coding gene in the species Homo sapiens

Caveolin-3 is a protein that in humans is encoded by the CAV3 gene. Alternative splicing has been identified for this locus, with inclusion or exclusion of a differentially spliced intron. In addition, transcripts utilize multiple polyA sites and contain two potential translation initiation sites.

<span class="mw-page-title-main">NOTCH3</span> Protein-coding gene in the species Homo sapiens

Neurogenic locus notch homolog protein 3(Notch 3) is a protein that in humans is encoded by the NOTCH3 gene.

<span class="mw-page-title-main">Photoreceptor cell-specific nuclear receptor</span> Protein-coding gene in the species Homo sapiens

The photoreceptor cell-specific nuclear receptor (PNR), also known as NR2E3, is a protein that in humans is encoded by the NR2E3 gene. PNR is a member of the nuclear receptor super family of intracellular transcription factors.

<span class="mw-page-title-main">Notch 1</span> Protein-coding gene in the species Homo sapiens

Neurogenic locus notch homolog protein 1(Notch 1) is a protein encoded in humans by the NOTCH1 gene. Notch 1 is a single-pass transmembrane receptor.

<span class="mw-page-title-main">Notch 2</span> Protein-coding gene in the species Homo sapiens

Neurogenic locus notch homolog protein 2 is a protein that in humans is encoded by the NOTCH2 gene.

<span class="mw-page-title-main">GPR143</span> Protein-coding gene in the species Homo sapiens

G-protein coupled receptor 143, also known as Ocular albinism type 1 (OA1) in humans, is a conserved integral membrane protein with seven transmembrane domains and similarities with G protein-coupled receptors (GPCRs) that is expressed in the eye and epidermal melanocytes. This protein encoded by the GPR143 gene, whose variants can lead to Ocular albinism type 1.

<span class="mw-page-title-main">Delta-like 1</span> Protein-coding gene in the species Homo sapiens

Delta-like protein 1 is a protein that in humans is encoded by the DLL1 gene.

<span class="mw-page-title-main">RBPJ</span> Protein-coding gene in the species Homo sapiens

Recombination signal binding protein for immunoglobulin kappa J region is a protein that in humans is encoded by the RBPJ gene.

<span class="mw-page-title-main">Endothelin 3</span> Protein-coding gene in the species Homo sapiens

Endothelin-3 is a protein that in humans is encoded by the EDN3 gene.

<span class="mw-page-title-main">HEY2</span> Protein-coding gene in the species Homo sapiens

Hairy/enhancer-of-split related with YRPW motif protein 2 (HEY2) also known as cardiovascular helix-loop-helix factor 1 (CHF1) is a protein that in humans is encoded by the HEY2 gene.

<span class="mw-page-title-main">JAG2</span> Protein-coding gene in the species Homo sapiens

Jagged-2 is a protein that in humans is encoded by the JAG2 gene.

<span class="mw-page-title-main">MFNG</span> Protein-coding gene in the species Homo sapiens

Beta-1,3-N-acetylglucosaminyltransferase manic fringe is an enzyme that in humans is encoded by the MFNG gene, a member of the fringe gene family which also includes the radical fringe (RFNG) and lunatic fringe (LFNG).

<span class="mw-page-title-main">CHRND</span> Protein-coding gene in the species Homo sapiens

Acetylcholine receptor subunit delta is a protein that in humans is encoded by the CHRND gene.

<span class="mw-page-title-main">CRLF1</span> Protein-coding gene in the species Homo sapiens

Cytokine receptor-like factor 1 is a protein that in humans is encoded by the CRLF1 gene.

<span class="mw-page-title-main">Notch proteins</span> Protein family

Notch proteins are a family of type 1 transmembrane proteins that form a core component of the Notch signaling pathway, which is highly conserved in animals. The Notch extracellular domain mediates interactions with DSL family ligands, allowing it to participate in juxtacrine signaling. The Notch intracellular domain acts as a transcriptional activator when in complex with CSL family transcription factors. Members of this type 1 transmembrane protein family share several core structures, including an extracellular domain consisting of multiple epidermal growth factor (EGF)-like repeats and an intracellular domain transcriptional activation domain (TAD). Notch family members operate in a variety of different tissues and play a role in a variety of developmental processes by controlling cell fate decisions. Much of what is known about Notch function comes from studies done in Caenorhabditis elegans (C.elegans) and Drosophila melanogaster. Human homologs have also been identified, but details of Notch function and interactions with its ligands are not well known in this context.

<span class="mw-page-title-main">TMEM216</span> Protein-coding gene in the species Homo sapiens

Transmembrane protein 216 is a protein in humans that is encoded by the TMEM216 gene.

In molecular biology, there are a number of neurogenic proteins referred to as mastermind-like proteins (MAMLs) of which this domain is the N-terminal region. Mastermind-like proteins act as critical transcriptional co-activators for Notch signaling.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000101384 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000027276 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. 1 2 Lindsell CE, Shawber CJ, Boulter J, Weinmaster G (1995). "Jagged: a mammalian ligand that activates Notch1". Cell. 80 (6): 909–17. doi: 10.1016/0092-8674(95)90294-5 . PMID   7697721. S2CID   11720367.
  6. 1 2 Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin A, Piccoli DA, Meltzer PS, Spinner NB, Collins FS, Chandrasekharappa SC (1997). "Mutations in the human Jagged1 gene are responsible for Alagille syndrome". Nat. Genet. 16 (3): 235–42. doi:10.1038/ng0797-235. PMID   9207787. S2CID   5775213.
  7. Guarnaccia C, Pintar A, Pongor S (2004). "Exon 6 of human Jagged-1 encodes an autonomously folding unit". FEBS Lett. 574 (1–3): 156–60. doi: 10.1016/j.febslet.2004.08.022 . PMID   15358557. S2CID   34651925.
  8. Shimizu K, Chiba S, Saito T, Kumano K, Hirai H (2000). "Physical interaction of Delta1, Jagged1, and Jagged2 with Notch1 and Notch3 receptors". Biochem. Biophys. Res. Commun. 276 (1): 385–9. doi:10.1006/bbrc.2000.3469. PMID   11006133.
  9. Shimizu K, Chiba S, Saito T, Kumano K, Takahashi T, Hirai H (July 2001). "Manic fringe and lunatic fringe modify different sites of the Notch2 extracellular region, resulting in different signaling modulation". J. Biol. Chem. 276 (28): 25753–8. doi: 10.1074/jbc.M103473200 . PMID   11346656.
  10. Shimizu K, Chiba S, Kumano K, Hosoya N, Takahashi T, Kanda Y, Hamada Y, Yazaki Y, Hirai H (November 1999). "Mouse jagged1 physically interacts with notch2 and other notch receptors. Assessment by quantitative methods". J. Biol. Chem. 274 (46): 32961–9. doi: 10.1074/jbc.274.46.32961 . PMID   10551863.
  11. Shimizu K, Chiba S, Hosoya N, Kumano K, Saito T, Kurokawa M, Kanda Y, Hamada Y, Hirai H (September 2000). "Binding of Delta1, Jagged1, and Jagged2 to Notch2 Rapidly Induces Cleavage, Nuclear Translocation, and Hyperphosphorylation of Notch2". Mol. Cell. Biol. 20 (18): 6913–22. doi:10.1128/MCB.20.18.6913-6922.2000. PMC   88767 . PMID   10958687.
  12. 1 2 Jones EA, Clement-Jones M, Wilson DI (2000). "JAGGED1 expression in human embryos: correlation with the Alagille syndrome phenotype". J. Med. Genet. 37 (9): 658–62. doi:10.1136/jmg.37.9.658. PMC   1734694 . PMID   10978356.
  13. 1 2 Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE (2005). "High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival". Cancer Res. 65 (18): 8530–7. doi: 10.1158/0008-5472.CAN-05-1069 . PMID   16166334.
  14. Simon DP, Giordano TJ, Hammer GD (2012). "Upregulated JAG1 enhances cell proliferation in adrenocortical carcinoma". Clin. Cancer Res. 18 (9): 2452–64. doi:10.1158/1078-0432.CCR-11-2371. PMC   3848076 . PMID   22427350.
  15. McCright B, Lozier J, Gridley T (2002). "A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency". Development. 129 (4): 1075–82. doi:10.1242/dev.129.4.1075. PMID   11861489.
  16. Loomes KM, Underkoffler LA, Morabito J, Gottlieb S, Piccoli DA, Spinner NB, Baldwin HS, Oakey RJ (1999). "The expression of Jagged1 in the developing mammalian heart correlates with cardiovascular disease in Alagille syndrome". Hum. Mol. Genet. 8 (13): 2443–9. doi: 10.1093/hmg/8.13.2443 . PMID   10556292.
  17. Hofmann JJ, Briot A, Enciso J, Zovein AC, Ren S, Zhang ZW, Radtke F, Simons M, Wang Y, Iruela-Arispe ML (2012). "Endothelial deletion of murine Jag1 leads to valve calcification and congenital heart defects associated with Alagille syndrome". Development. 139 (23): 4449–60. doi:10.1242/dev.084871. PMC   3509736 . PMID   23095891.
  18. Hofmann JJ, Zovein AC, Koh H, Radtke F, Weinmaster G, Iruela-Arispe ML (2010). "Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndrome". Development. 137 (23): 4061–72. doi:10.1242/dev.052118. PMC   2976287 . PMID   21062863.
  19. High FA, Lu MM, Pear WS, Loomes KM, Kaestner KH, Epstein JA (2008). "Endothelial expression of the Notch ligand Jagged1 is required for vascular smooth muscle development". Proc. Natl. Acad. Sci. U.S.A. 105 (6): 1955–9. Bibcode:2008PNAS..105.1955H. doi: 10.1073/pnas.0709663105 . PMC   2538864 . PMID   18245384.
  20. Humphreys R, Zheng W, Prince LS, Qu X, Brown C, Loomes K, Huppert SS, Baldwin S, Goudy S (2012). "Cranial neural crest ablation of Jagged1 recapitulates the craniofacial phenotype of Alagille syndrome patients". Hum. Mol. Genet. 21 (6): 1374–83. doi:10.1093/hmg/ddr575. PMC   3465692 . PMID   22156581.
  21. 1 2 Krantz ID, Colliton RP, Genin A, Rand EB, Li L, Piccoli DA, Spinner NB (1998). "Spectrum and frequency of jagged1 (JAG1) mutations in Alagille syndrome patients and their families". Am. J. Hum. Genet. 62 (6): 1361–9. doi:10.1086/301875. PMC   1377154 . PMID   9585603.
  22. Warthen DM, Moore EC, Kamath BM, Morrissette JJ, Sanchez-Lara PA, Sanchez P, Piccoli DA, Krantz ID, Spinner NB (2006). "Jagged1 (JAG1) mutations in Alagille syndrome: increasing the mutation detection rate". Hum. Mutat. 27 (5): 436–43. doi:10.1002/humu.20310. PMID   16575836. S2CID   45080348.
  23. Penton AL, Leonard LD, Spinner NB (2012). "Notch signaling in human development and disease". Semin. Cell Dev. Biol. 23 (4): 450–7. doi:10.1016/j.semcdb.2012.01.010. PMC   3638987 . PMID   22306179.
  24. Morrissette JD, Colliton RP, Spinner NB (2001). "Defective intracellular transport and processing of JAG1 missense mutations in Alagille syndrome". Hum. Mol. Genet. 10 (4): 405–13. doi: 10.1093/hmg/10.4.405 . PMID   11157803.
  25. Crosnier C, Driancourt C, Raynaud N, Dhorne-Pollet S, Pollet N, Bernard O, Hadchouel M, Meunier-Rotival M (1999). "Mutations in JAGGED1 gene are predominantly sporadic in Alagille syndrome". Gastroenterology. 116 (5): 1141–8. doi:10.1016/S0016-5085(99)70017-X. PMID   10220506.
  26. Bauer RC, Laney AO, Smith R, Gerfen J, Morrissette JJ, Woyciechowski S, Garbarini J, Loomes KM, Krantz ID, Urban Z, Gelb BD, Goldmuntz E, Spinner NB (2010). "Jagged1 (JAG1) mutations in patients with tetralogy of Fallot or pulmonic stenosis". Hum. Mutat. 31 (5): 594–601. doi:10.1002/humu.21231. PMC   2914103 . PMID   20437614.
  27. Dickson BC, Mulligan AM, Zhang H, Lockwood G, O'Malley FP, Egan SE, Reedijk M (2007). "High-level JAG1 mRNA and protein predict poor outcome in breast cancer". Mod. Pathol. 20 (6): 685–93. doi: 10.1038/modpathol.3800785 . PMID   17507991.
  28. Li D, Masiero M, Banham AH, Harris AL (2014). "The notch ligand JAGGED1 as a target for anti-tumor therapy". Front Oncol. 4: 254. doi: 10.3389/fonc.2014.00254 . PMC   4174884 . PMID   25309874.
  29. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK (2007). "Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma". Cancer Res. 67 (4): 1757–68. doi: 10.1158/0008-5472.CAN-06-3700 . PMID   17308118.

Further reading

This article incorporates text from the United States National Library of Medicine, which is in the public domain.